President Joe Biden’s Inflation Reduction Act allows Medicare to negotiate costly drug prices with pharmaceutical companies.

Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

This news of Ozempic price cuts comes on the heels, or tablet, of Novo Nordisk developing a weight loss pill that mirrors the ...

Americans are paying more than $900 a month for popular weight-loss drugs Ozempic and Wegovy, but drugmakers want to sell ...

Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a ...

Ozempic can therefore also lead to weight loss, as the drug also reduces appetite, as well as delaying the rate at which food ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

The ability to negotiate drug prices is part of a sweeping set of policies in President Joe Biden’s Inflation Reduction Act.

The latest health news includes Sen. Sanders advocating for affordable Ozempic, Neuralink's FDA 'breakthrough' for Blindsight ...

Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company ...

A top executive at Novo Nordisk (NVO) warned Tuesday that the company’s diabetes therapy Ozempic will likely be selected for ...